Thousand Oaks Biopharmaceutical Group has signed a joint venture agreement with a Korean biotech company in which they will boost serum-free cell culture media production, the companies said on Wednesday.
Cell culture media, a liquid or gel designed to support microorganism growth for lab use, will be developed to meet commercial demand on an international scale, according to venture terms.
T.O. Bio’s subsidiary, JS Biosciences, will play an integral role in the venture as the current leading cell culture media supplier to China.
The deal is with WSG Group, and the venture will focus on building a cell culture media production center in Korea with “significant capacity” this year, the companies said in a statement. The center will be Korea’s first local company for cell culture media, with the ability to produce thousands of kilograms in batch capacity.
Posted on 7702
January 2021, Thousand Oaks Biopharmaceuticals Group (“Thousand Oaks”) announced that it had signed a Joint Venture agreement with WSG Group in Busan, Korea, to establish a bioprocess solution joint venture (including cell culture media, single-use technology, and related technologies and products) in early 2021. The Joint Venture will speed up and boost development of the Korean Biopharmaceutical industry by supplying serum-free cell culture media at commercial scale. This cooperation also marks another milestone for JSBiosciences (a fully owned subsidiary of Thousand Oaks) the leading cell culture media supplier to enter the international market.
Thousand Oaks Biopharmaceuticals Inked a Joint Venture Agreement with Korea’s WSG Group (Graphic: Business Wire)
Thousand Oaks Biopharmaceuticals Inked a Joint Venture Agreement with Korea’s WSG Group
By
Staff
2 months ago
THOUSAND OAKS, Calif. & SHANGHAI & BUSAN, South Korea–(BUSINESS WIRE)–#ASMEBPEcertification–January 2021, Thousand Oaks Biopharmaceuticals Group (“Thousand Oaks”) announced that it had signed a Joint Venture agreement with WSG Group in Busan, Korea, to establish a bioprocess solution joint venture (including cell culture media, single-use technology, and related technologies and products) in early 2021. The Joint Venture will speed up and boost development of the Korean Biopharmaceutical industry by supplying serum-free cell culture media at commercial scale. This cooperation also marks another milestone for JSBiosciences (a fully owned subsidiary of Thousand Oaks) the leading cell culture media supplier to enter the international market.
Share:
Jianshun Biosciences Co., Ltd. ( JS Bio ) recently announced its strategic partnership with Etta Biotech Co., Ltd. ( Etta Biotech ), to set up a high titer transient protein expression platform for high quality protein production using JS Bio s transient transfection media. JS Bio becomes the exclusive cell culture supplier for Etta Biotech s transient transfection high titer protein expression platform.
Dr. Edward Dai, Chairman and CEO of Etta Biotech (left); Dr. Luo Shun, Chairman and President of JS Bio (right) (Photo: Business Wire)
Etta Biotech is a leading cell electroporation technology and equipment supplier. Its proprietary large-capacity flow electroporator, X-Porator F1, is one of the only two products of its kind in the world, and leads the market with its outstanding performance and customer value. Etta Biotech s F1 equipment, paired with a completed process optimization protocol, can significantly increase protein expression titer and quality with transient tr